You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
661 Dipeptidyl peptidase-9 (DPP9) overexpression is a potential response-predictive biomarker of BXCL701 and pembrolizumab combination treatment in mCRPC patients with SCNC phenotype

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023140010
Dec 20232004
Jan 202418906
Feb 20243601
Mar 20243200
Apr 20242002
May 20242802
Jun 20242103
Jul 20243404
Aug 20242002
Sep 20243207
Oct 20241805
Nov 20241802
Dec 20242009
Jan 20252606
Feb 2025404
Mar 2025004
Apr 2025101
May 2025003
Jun 2025002
Total659077